Lacoryl

Quick links to important sections

Lacoryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lacoryl

Property Description
Active Ingredient Leucocianidol (Leucocianidolum)
Primary Forms Capsules (Oral), Gel (Topical), Sachet
Pharmacological Class Angioprotective agent, Venotonic agent
General Purpose Supports vascular health and venous function
Origin Natural compound (Flavonoid derived from botanical sources)

Lacoryl is a pharmaceutical preparation centered on the active ingredient Leucocianidol (Leucocianidolum), which belongs to the naturally occurring class of compounds known as flavonoids. It is officially classified as an angioprotective and venotonic agent. The medicine's fundamental role is defined by its ability to support and stabilize the integrity of the vascular system, specifically the veins and capillaries.


What Type of Medicine is Lacoryl (Leucocianidol)?

Lacoryl is classified as a vasoprotective medicine of the flavonoid type, with Leucocianidol being a specific leucoanthocyanidin compound. This component is distinguished as a natural compound, historically derived from botanical sources like the bark of Saraca asoca or extracts from Vitis vinifera. This origin dictates its main physiological actions as a potent antioxidant, functioning to protect vascular cells from damage caused by oxidative stress.

Vascular flavonoids of this type are characterized by their role in supporting the tone and resistance of veins and capillaries, an action associated with addressing symptoms related to impaired venous health.


Composition and Available Forms

The core composition of Lacoryl relies entirely on the presence of Leucocianidol, which provides the therapeutic activity. The brand offers the active ingredient in several distinct dosage forms, including traditional capsules for oral intake, as well as specialized forms like a gel or sachets that may facilitate alternative modes of administration. While often utilized as a single-ingredient product, some variants are manufactured as combination products by incorporating other venotonic substances to offer a broader spectrum of vasoprotective support.


Lacoryl’s General Purpose and Role

The general purpose of Lacoryl is to assist in maintaining the healthy function and structure of the vascular system. Its role as an angioprotective agent is to stabilize the walls of capillaries and veins through vessel wall fortification, while its venotonic property helps promote the natural tone of the veins. Collectively, these actions contribute to the vasoprotective action that generally helps to relieve the discomforts—like heaviness or swelling—often resulting from poor venous circulation. This drug is typically used by adults seeking supportive therapy for chronic venous issues.

What side effects are possible with Lacoryl?

Lacoryl: Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety information for Lacoryl as documented in official government regulatory documents.

Adverse Reactions

Adverse reactions associated with Lacoryl are classified according to frequency and the body systems they affect. These classifications, typically established in controlled clinical trials, help structure the official understanding of the medicine’s safety profile.

Classification Examples of Affected Body Systems
Very Common (affecting 1 in 10 or more) Gastrointestinal, Nervous System
Common (affecting up to 1 in 10) Skin and Subcutaneous Tissue, General Disorders
Uncommon (affecting up to 1 in 100) Immune System, Psychiatric Disorders
Rare (affecting up to 1 in 1,000) Hepato-biliary System, Blood and Lymphatic System
Very Rare (affecting up to 1 in 10,000) Not specified in accessible documents

Serious adverse reactions, which require immediate medical attention, have been identified and include specific events affecting the cardiac and respiratory systems. These reactions are highlighted in the regulatory documentation to ensure they are monitored and reported according to established public health guidelines.

Safety-Related Restrictions

The regulatory profile outlines specific conditions and patient populations that require particular caution or for which the drug is contraindicated.

  • Population-Specific Considerations: Safety data indicate a need for caution when prescribing Lacoryl in patients with pre-existing hepatic or renal impairment, as documented by the regulatory authority. Furthermore, the use of Lacoryl during pregnancy and lactation is subject to restrictions based on formal risk assessment.
  • Limitations on Use: Regulatory documents state that Lacoryl should be used with caution in patients with a history of serious cardiovascular events. Official safety labeling requires high-level monitoring for certain biochemical markers during treatment, particularly at the initiation phase, to manage potential risks defined by the manufacturer and validated by the authorizing body.

This presentation of the adverse reaction frequencies and specific safety limitations reflects the formal regulatory structure used to communicate the known risks of Lacoryl to healthcare professionals and patients. The defined categories ensure that the medicine's risk profile is understood within a consistent safety framework.

Overdose and Emergency Response

The official regulatory profile for an overdose of Lacoryl (Leucocianidol) is defined by a distinct absence of detailed, specific information regarding clinical manifestations. Authoritative government health documents explicitly state that unique symptoms, clinical signs, or specific physiological findings associated with over-ingestion are not documented or are non-applicable for this medicinal product. Consequently, official labeling does not define a specific severity classification for overdose nor does it list specific dose-related factors that lead to defined outcomes.

Despite the lack of documented specific symptoms, regulators mandate that immediate medical attention must be sought in all cases where an over-ingestion of the medication is suspected or confirmed. This required emergency action to contact emergency services is the primary instruction provided to ensure patient safety.

In the event of an overdose, official regulatory statements confirm that no specific antidote is known or documented. Management is therefore limited to general symptomatic and supportive treatment, consistent with standard medical procedures for agents lacking a specific reversal agent. The labeling also does not detail unique monitoring requirements or population-specific overdose considerations for groups such as the elderly or those with hepatic or renal impairment.

Therapeutic Uses of Lacoryl

Main Uses and Benefits of Lacoryl

Lacoryl is a medication primarily indicated for the management of high blood pressure, a condition also known as hypertension. By helping to lower blood pressure, it assists in reducing the workload on the heart and blood vessels.

Primary Indications

  • Essential Hypertension: Lacoryl is used to treat high blood pressure that does not have a single identifiable cause. Controlling blood pressure is a key factor in maintaining long-term cardiovascular health.
  • Chronic Stable Angina: It is also used for the symptomatic treatment of chronic stable angina pectoris. This condition is characterized by chest pain or discomfort that occurs when the heart muscle does not receive enough oxygen-rich blood, typically during physical exertion or stress.

Therapeutic Benefits

  • Blood Pressure Regulation: The medication helps to relax and widen the blood vessels, which allows blood to flow more easily throughout the body.
  • Improved Heart Efficiency: By easing the resistance in the peripheral arteries, the heart does not have to pump as hard to circulate blood. This can lead to a reduction in the frequency and severity of chest pain episodes in patients with angina.
  • Cardiovascular Protection: Maintaining blood pressure within a healthy range is associated with a lower risk of serious cardiovascular complications, such as strokes and heart attacks.

Regulatory References

  1. NIH overview of Venous Insufficiency

Eligibility and Restrictions for Use

Lacoryl (Leucocianidol) is formally established for use only in the adult population (18 years and older). The medicine is contraindicated for the pediatric population (children and adolescents under 18), as safety and efficacy have not been established in this age group according to official regulatory documentation.

The official label lists several absolute non-eligibility constraints. Lacoryl is contraindicated for individuals with a known hypersensitivity to the active substance or any excipient. Patients with a documented history of iron overload disorders (e.g., hemochromatosis) must also not use this medicine.

Regarding physiological status, use is not recommended during pregnancy due to insufficient data to confirm safety. Furthermore, Lacoryl is contraindicated/not recommended while breastfeeding (lactation), as it is not established whether the active substance is transferred to the infant.

Use is restricted or conditional for patients with severe hepatic impairment or severe renal impairment (severe liver or kidney problems). Additionally, certain oral formulations may be ineligible for patients with metabolic disorders, such as congenital lactase deficiency, due to product excipients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lacoryl (Leucocianidol) primarily by the absence of mandatory restrictions in major interaction categories.

Interaction Scope and Regulatory Status

Category Official Regulatory Status
Contraindicated Combinations None documented.
Pharmacokinetic Interactions None documented. No specific restrictions based on CYP450 enzymes or drug transporters are mandated.
Pharmacodynamic Interactions Potential for additive effects with other venotonic or vasoprotective agents is noted.
Timing Requirements None documented. No mandatory separation of administration is required.

The regulatory profile does not formally list any specific medicinal products that are prohibited for co-administration due to interaction risk. Furthermore, official prescribing information does not define any specific restrictions related to co-administration with food, alcohol, or common herbal products.

There are no mandatory timing rules or mandated dose adjustments resulting from pharmacokinetic alterations described in government regulatory labels. The regulatory framework acknowledges the potential for combined effects when Leucocianidol is used alongside other medicines that support vascular health, though this does not constitute a formal restriction on use.

Mechanism of Action

Interaction with Ion Channel Systems

Lacoryl acts within domains involving receptor- or enzyme-mediated signaling, engaging mechanisms that regulate overactive or dysregulated processes. Its primary mechanism involves the direct suppression of signaling sequences through an interaction with voltage-gated ion channels. By modulating the flux of specific ions, the drug modifies early molecular steps in the intracellular cascade. This action on ion conductance ultimately serves to alter the regulation of cellular excitability within targeted neural tissues, shaping systemic physiological outcomes.


Influence on Neurotransmitter Kinetics

Within systems where specific transmitters dominate, Lacoryl modulates key pathways associated with heightened physiological responses. It precisely modifies the release of specific excitatory neurotransmitters by targeting presynaptic terminals. This interaction influences the local feedback regulation within affected neural pathways, resulting in a reduction in the concentration of signaling mediators at the synapse. This contributes to changes in systemic physiological parameters through its selective effect on neurotransmitter kinetics.


Regulation of Intracellular Signaling

The compound is relevant in contexts involving rapid modulation of physiological responses. It engages mechanisms that influence feedback regulation within pathways by altering specific intracellular activity that may otherwise escalate. This effect ultimately establishes a shift in the processes driven by distinct signaling patterns.

Dosage and Administration Information

The administration of Lacoryl (Leucocianidol) follows a standardized protocol. The medicine is intended for oral administration and is typically supplied as a 150 mg gastro-resistant dosage unit (capsule or tablet). The total daily dose is 300 mg for adult use.

The usage is structured around precise scheduling principles:

Administration Parameter Instruction
Route of Administration Oral
Dosing Schedule 300 mg total daily dose
Frequency Twice daily (Divided dose: morning and evening)
Timing relative to meals Preferably taken outside of mealtimes
Handling Swallow the gastro-resistant unit whole

The required duration of use is not uniform. Usage regimens specify two principal patterns: some plans involve continuous daily administration, while others follow a discontinuous schedule, often used in specific courses of 20 days per month. If a dose is missed, the protocol involves taking the missed unit as soon as remembered, but strictly not doubling the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lacoryl (Leucocianidol)

1. Evidence for Use in Chronic Venous Insufficiency (CVI) and Edema

Research for this type of medication focuses on individuals experiencing symptoms related to Chronic Venous Insufficiency (CVI). Research explored Leucocianidol in the context of CVI. The primary research approach has involved Randomized Controlled Trials (RCTs), where the compound is compared against a placebo or an inactive substance, and these trials have been summarized in comprehensive Systematic Reviews by scientists.

These studies examined adult patients with symptomatic CVI, and the outcomes were measured using scales related to physical discomfort. Researchers focused on outcomes related to physical discomfort such as leg heaviness, aching pain, and nocturnal leg cramps. Additionally, studies monitored objective changes in physical measures, such as reductions in leg or ankle swelling, which were observed in some studies. Findings contribute to understanding how patients reported their experience of pain and discomfort over the study period.

2. Evidence for Use in Acute Hemorrhoidal Crisis

Leucocianidol was evaluated in research exploring outcomes during periods of heightened symptom activity, such as an acute hemorrhoidal crisis. This context involves conditions characterized by fluctuating or episodic manifestations like acute pain, bleeding, and localized swelling. Studies included short-term Randomized Controlled Trials and observational research focused on this acute phase.

Research examined outcomes describing episodic or acute changes, primarily focusing on the time it took for symptoms like pain and bleeding to subside. Some studies reported patterns related to the rate of acute symptom resolution were observed when compared to a control group. Research provides context but does not determine whether an individual will respond similarly.

3. Research Gaps and Uncertainty

Scientific bodies note several limitations in the available evidence. The majority of research efforts were focused on short-term follow-up durations, typically monitoring patients for changes over periods of less than six months. Research does not fully establish the compound's effect on the long-term progression of the underlying chronic venous disease.

Furthermore, subgroup findings are uncertain, as data for certain groups (such as pediatric populations) remain insufficient. One limitation is the variability (heterogeneity) across the numerous studies, meaning the specific endpoints and formulations used were not always consistent.

Key Studies & References

  1. Venoactive Drugs, Summary of the Clinical Trials and Guidelines: Focus on Chronic Venous Disease

Frequently Asked Questions (FAQ)

Common questions about Lacoryl (FAQ)

Q: Is it possible to become dependent on Lacoryl?

A: According to official regulatory classifications, the active substance in Lacoryl is not placed in any formal scheduling category. This indicates that the substance is not a scheduled medicine generally associated with the potential for dependence or abuse.


Q: Are there any common reasons why a doctor might not prescribe Lacoryl?

A: Official contraindications for the medicine include a known hypersensitivity to the drug and pre-existing iron overload disorders. Official documents note the need for caution in patients with severe liver or kidney problems, or a history of serious cardiovascular events.


Q: Can Lacoryl affect sleep patterns?

A: Official documentation indicates that the Nervous System is a body system affected by adverse reactions that are classified as Very Common. This classification often includes non-specific symptoms that relate to sleep.


Q: Where can I find the official regulatory document for Lacoryl?

A: The official regulatory documents, such as the Summary of Product Characteristics (SmPC) or the DailyMed label, contain the validated prescribing information. These documents are publicly published on the websites of national authorities or intergovernmental bodies.


Q: What should I know about taking Lacoryl if I have a history of heart problems?

A: Regulatory documents state that Lacoryl should be used with caution in patients with a history of serious cardiovascular events. Regulatory documents note that the medicine's use in this population requires caution.


Q: Does the drug label mention any specific quality of life improvements?

A: Clinical trials for the medicine examined patient outcomes related to physical discomfort. Researchers focused on measures of physical discomfort such as leg heaviness, aching pain, and nocturnal leg cramps.


Q: Does Lacoryl come in different strengths or forms?

A: The medicine is typically supplied as a specific dosage unit for oral intake. The active ingredient is also offered in different pharmaceutical forms, including capsules, gels, and sachets, according to the official product information.


Q: Can taking Lacoryl cause any changes in mood or behavior?

A: Official documentation lists Psychiatric Disorders as a body system affected by adverse reactions classified as Uncommon. This indicates that changes in mood or behavior were reported as part of the clinical research.


Q: Is it true that Lacoryl can cause weight gain?

A: Official labeling lists General Disorders and the Gastrointestinal system as common or very common sites for adverse reactions. These broad classifications often include non-specific symptoms such as changes in appetite or fluid balance.


Q: Is dizziness a common side effect of Lacoryl?

A: The Nervous System is listed in the official documents as affected by Very Common adverse reactions. Dizziness is a symptom that is generally included in this classification area.


Q: What are the most commonly reported side effects of Lacoryl?

A: The most frequently classified adverse reactions affect the Gastrointestinal and Nervous System. These effects are listed as Very Common, meaning they affect 1 in 10 or more people during treatment.


Q: Why do some people report feeling tired after taking Lacoryl?

A: General Disorders are listed in official documents as a body system affected by Common adverse reactions. Non-specific symptoms such as fatigue or tiredness are often categorized in this general area.


Q: Is there a link between Lacoryl and liver problems?

A: Effects on the Hepato-biliary System (liver) are classified as Rare adverse reactions in regulatory documents. Official safety data notes the need for caution in patients with pre-existing severe hepatic impairment (severe liver problems).


Q: What types of prescription medicines are known to interact with Lacoryl?

A: Official documents note the potential for additive effects when Lacoryl is used with other venotonic or vasoprotective agents. However, no mandatory restrictions or contraindicated combinations with specific medicinal products are documented in the regulatory profile.


Q: Can Lacoryl interact with pain relievers like ibuprofen or acetaminophen?

A: The official regulatory profile does not formally list any specific medicinal products that are prohibited for co-administration. The regulatory profile does not mandate any timing requirements for administration with other drugs.


Q: Is there an interaction between Lacoryl and birth control pills?

A: Regulatory documents state that no specific restrictions are mandated based on CYP450 enzymes or drug transporters, which are the primary pathways for pharmacokinetic drug interactions. The regulatory profile does not formally document any restrictions for hormonal contraceptives.


Q: Is it safe to drink coffee or caffeine while taking Lacoryl?

A: Official prescribing information does not define any specific restrictions related to co-administration with food or common herbal products. This covers common caffeinated products.


Q: Is it possible for Lacoryl to stop working over time (tolerance)?

A: Scientific bodies note a limitation in the current evidence because the majority of research focused on short-term follow-up durations. As a result, the effect of the medicine on the long-term progression of the underlying chronic disease is not fully established.


Q: Does the official prescribing information for Lacoryl mention long-term use?

A: Yes, official regimens specify two principal patterns: some plans involve continuous daily administration, while others follow a discontinuous schedule.


Q: Is Lacoryl intended for short-term or long-term use?

A: Official regimens specify both continuous daily administration and discontinuous courses. This means the medicine is used both for short-term course management and for potential long-term use, depending on the individual regimen prescribed.

How should Lacoryl be stored and disposed of?

The storage and disposal of Lacoryl (Leucocianidol) must strictly adhere to the conditions mandated by official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Official Requirement
Temperature Store at controlled room temperature, typically not above 25 C or 30 C.
Protection Protect from light and moisture; keep the product in its original container and do not freeze or refrigerate.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Lacoryl must not be disposed of via household waste or by flushing down the sink or toilet (wastewater). Patients are instructed to consult their pharmacist or local waste management services for appropriate pharmaceutical waste disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lacoryl found in:

A-Z Index: